(HealthDay)—The first biosimilar to Lucentis (ranibizumab injection) has been approved for the treatment of neovascular (wet) age-related macular degeneration and other eye diseases and conditions, the U.S. Food and Drug Administration announced Friday. The approval of the biosimilar, Byooviz (ranibizumab-nuna), is also indicated to treat macular edema after retinal vein occlusion and myopic choroidal neovascularization. Byooviz is...
by University of Utah Health Sciences A fundus photo showing intermediate age-related macular degeneration. Credit: National Eye Institute, National Institutes of Health Research conducted at the Sharon Eccles Steele Center for Translational Medicine (SCTM) at the University of Utah’s John A. Moran Eye Center explains why people carrying a block of genetic variants strongly associated with the...
by Britney Pennington and Lincoln V. Johnson, University of California – Santa Barbara Credit: CC0 Public Domain Scientists at UC Santa Barbara, University of Southern California (USC), and the biotechnology company Regenerative Patch Technologies LLC (RPT) have reported new methodology for the preservation of RPT’s stem cell-based therapy for age-related macular degeneration (AMD). The new research,...
by University of Rochester An illustration of the lab model that mimics the part of the human retina affected in macular degeneration. The model combines stem cell-derived retinal tissue and vascular networks from human patients with bioengineered synthetic materials in a 3D “matrix.” Credit: University of Rochester illustration / Michael Osadciw Age-related macular degeneration (AMD), which...
A team of researchers led by the University of Wisconsin–Madison professor David Gamm is developing a transplantable retinal patch intended to help restore vision to military personnel blinded in the line of duty and to treat individuals with degenerative eye diseases such as macular degeneration. Retina is the only part of the central nervous system...
The widely used and well-tolerated drug commonly used to treat Parkinson’s disease may help significantly reduce the need for more costly, more invasive treatments, report investigators in The American Journal of Medicine ELSEVIER IMAGE: SPECTRAL DOMAIN ? OPTICAL COHERENCE TOMOGRAPHY IMAGES OF THE SAME MACULAR SEGMENTATION LINE AT BASELINE AND MONTHLY FOLLOW-UP VISITS IN A...
EXERCISE CAN SLOW OR PREVENT THE DEVELOPMENT OF MACULAR DEGENERATION AND MAY BENEFIT OTHER COMMON CAUSES OF VISION LOSS, SUCH AS GLAUCOMA AND DIABETIC RETINOPATHY, ACCORDING TO NEW RESEARCH FROM… view more CREDIT: DAN ADDISON | UVA COMMUNICATIONS Exercise can slow or prevent the development of macular degeneration and may benefit other common causes of...
by David J. Hill, University at Buffalo Participants who ate a diet high in red and processed meat, fried food, refined grains and high-fat dairy were three times more likely to develop an eye condition that damages the retina and affects a person’s central vision, according to the results of a study from the University...
by Bill Hathaway, Yale University Age-related macular degeneration is one of the leading causes of blindness in the elderly, affecting more than 2 million people in the United States and leading to progressive loss of central vision. Genome wide studies have identified almost three dozen genes that play a role in the disease, but exactly...
by Sanford Burnham Prebys Medical Discovery Institute Scientists at Sanford Burnham Prebys have identified the long-sought structure of an essential blood protein: vitronectin. Knowing the protein’s structure—an advance that enables rational drug design—could lead to medicines that kill multi-drug-resistant bacteria, halt cancer metastasis, treat age-related macular degeneration (AMD) and more. The study was published in...
